{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T06:16:25Z","timestamp":1792995385584,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangci Innovative Technology Launch Plan of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","award":["YW20220014"],"award-info":[{"award-number":["YW20220014"]}]},{"name":"Guangci Innovative Technology Launch Plan of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","award":["YW20240038"],"award-info":[{"award-number":["YW20240038"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-025-05826-2","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T08:11:03Z","timestamp":1759738263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["USP4-Mediated deubiquitination of A2AR suppresses autophagy-dependent ferroptosis in gastric cancer"],"prefix":"10.1007","volume":"82","author":[{"given":"Xuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Gang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3397-1992","authenticated-orcid":false,"given":"Chao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"issue":"3","key":"5826_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3322\/caac.21657","volume":"71","author":"J SS","year":"2021","unstructured":"SS J (2021) Current treatment and recent progress in gastric cancer. Cancer J Clin 71(3):264\u2013279","journal-title":"Cancer J Clin"},{"key":"5826_CR2","doi-asserted-by":"crossref","unstructured":"H L, M S, S W (2024) Current therapies and progress in the treatment of advanced gastric cancer. Front Oncol 14:1327055","DOI":"10.3389\/fonc.2024.1327055"},{"issue":"7","key":"5826_CR3","doi-asserted-by":"crossref","first-page":"101042831771462","DOI":"10.1177\/1010428317714626","volume":"39","author":"ZS Y","year":"2017","unstructured":"Y ZS (2017) Progress in the treatment of advanced gastric cancer. Tumour Biology: J Int Soc Oncodevelopmental Biology Med 39(7):1010428317714626","journal-title":"Tumour Biology: J Int Soc Oncodevelopmental Biology Med"},{"key":"5826_CR4","doi-asserted-by":"publisher","unstructured":"Lei G, Zhuang L, Gan B (2022) Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer 22(7):381\u2013396. https:\/\/doi.org\/10.1038\/s41568-022-00459-0","DOI":"10.1038\/s41568-022-00459-0"},{"issue":"12","key":"5826_CR5","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1039\/D3CS00001J","volume":"52","author":"N Kang","year":"2023","unstructured":"Kang N, Son S, Min S, Hong H, Kim C, An J et al (2023) Stimuli-responsive ferroptosis for cancer therapy. Chem Soc Rev 52(12):3955\u20133972","journal-title":"Chem Soc Rev"},{"issue":"3","key":"5826_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.tcb.2022.11.003","volume":"33","author":"H Yan","year":"2023","unstructured":"Yan H, Talty R, Johnson CH (2023) Targeting ferroptosis to treat colorectal cancer. Trends Cell Biol 33(3):185\u2013188","journal-title":"Trends Cell Biol"},{"key":"5826_CR7","doi-asserted-by":"publisher","first-page":"100977","DOI":"10.1016\/j.drup.2023.100977","volume":"70","author":"J Yu","year":"2023","unstructured":"Yu J, Zhong B, Zhao L, Hou Y, Ai N, Lu JJ et al (2023) Fighting drug-resistant lung cancer by induction of NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated ferroptosis. Drug Resist Updat 70:100977","journal-title":"Drug Resist Updat"},{"key":"5826_CR8","doi-asserted-by":"publisher","first-page":"860344","DOI":"10.3389\/fcell.2022.860344","volume":"10","author":"R Gu","year":"2022","unstructured":"Gu R, Xia Y, Li P, Zou D, Lu K, Ren L et al (2022) Ferroptosis and its role in gastric Cancer. Front Cell Dev Biol 10:860344","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"5826_CR9","first-page":"264","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Badgwell BD (2021) Current treatment and recent progress in gastric cancer. CA Cancer J Clin 71(3):264\u2013279","journal-title":"CA Cancer J Clin"},{"issue":"1\u20133","key":"5826_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/ars.2022.0202","volume":"39","author":"F Chen","year":"2023","unstructured":"Chen F, Cai X, Kang R, Liu J, Tang D (2023) Autophagy-Dependent ferroptosis in Cancer. Antioxid Redox Signal 39(1\u20133):79\u2013101","journal-title":"Antioxid Redox Signal"},{"key":"5826_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s12935-020-01391-9","volume":"20","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhou L, Lu J, Jiang B, Liu C, Guo J (2020) USP4 function and multifaceted roles in cancer: a possible and potential therapeutic target. Cancer Cell Int 20:298","journal-title":"Cancer Cell Int"},{"key":"5826_CR12","doi-asserted-by":"publisher","unstructured":"Hu B, Zhang D, Zhao K, Wang Y, Pei L, Fu Q et al (2021) Spotlight on USP4: structure, function, and regulation. Front Cell Dev Biol 9.\u00a0https:\/\/doi.org\/10.3389\/fcell.2021.595159","DOI":"10.3389\/fcell.2021.595159"},{"issue":"9","key":"5826_CR13","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.molonc.2015.06.006","volume":"9","author":"SI Yun","year":"2015","unstructured":"Yun SI, Kim HH, Yoon JH, Park WS, Hahn MJ, Kim HC et al (2015) Ubiquitin specific protease 4 positively regulates the WNT\/\u03b2-catenin signaling in colorectal cancer. Mol Oncol 9(9):1834\u20131851","journal-title":"Mol Oncol"},{"issue":"6","key":"5826_CR14","first-page":"1115","volume":"20","author":"WH Cao","year":"2016","unstructured":"Cao WH, Liu XP, Meng SL, Gao YW, Wang Y, Ma ZL et al (2016) USP4 promotes invasion of breast cancer cells via Relaxin\/TGF-\u03b21\/Smad2\/MMP-9 signal. Eur Rev Med Pharmacol Sci 20(6):1115\u20131122","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"5826_CR15","doi-asserted-by":"publisher","first-page":"216836","DOI":"10.1016\/j.canlet.2024.216836","volume":"589","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Li H, Zhang Y, Zhao E, Huang C, Pan X et al (2024) Deubiquitinase USP4 suppresses antitumor immunity by inhibiting IRF3 activation and tumor cell-intrinsic interferon response in colorectal cancer. Cancer Lett 589:216836","journal-title":"Cancer Lett"},{"key":"5826_CR16","doi-asserted-by":"crossref","unstructured":"Y T, W Y (2022) The deubiquitinating enzyme USP4 functions as an oncoprotein in gastric Cancer and mediates NF-\u03baB signaling by regulating PRL-3 expression. Front Biosci (Landmark edition) 27(10):286","DOI":"10.31083\/j.fbl2710286"},{"key":"5826_CR17","doi-asserted-by":"publisher","unstructured":"Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X (2016) Ferroptosis is an autophagic cell death process. Cell Res 26(9):1021\u201332. https:\/\/doi.org\/10.1038\/cr.2016.95","DOI":"10.1038\/cr.2016.95"},{"key":"5826_CR18","doi-asserted-by":"publisher","unstructured":"Chen F, Cai X, Kang R, Liu J, Tang D (2023) Autophagy-dependent ferroptosis in Cancer. Antioxid Redox Sign 39(1\u20133):79\u2013101. https:\/\/doi.org\/10.1089\/ars.2022.0202","DOI":"10.1089\/ars.2022.0202"},{"key":"5826_CR19","doi-asserted-by":"publisher","first-page":"121390","DOI":"10.1016\/j.jhazmat.2019.121390","volume":"384","author":"SWTQ X","year":"2020","unstructured":"X SWTQ (2020) Arsenic induces pancreatic dysfunction and ferroptosis via mitochondrial ROS-autophagy-lysosomal pathway. J Hazard Mater 384:121390","journal-title":"J Hazard Mater"},{"key":"5826_CR20","doi-asserted-by":"crossref","unstructured":"H Z, Y H, W X, Y G, Z S, P R et al (2023)\u00a0USP4 promotes the proliferation, migration, and invasion of esophageal squamous cell carcinoma by targeting TAK1. Cell Death Dis 14(11):730","DOI":"10.1038\/s41419-023-06259-0"},{"issue":"1","key":"5826_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41420-022-00820-0","volume":"8","author":"TD EY","year":"2022","unstructured":"EY TD, HJ L, EE Y (2022) USP15 and USP4 facilitate lung cancer cell proliferation by regulating the alternative splicing of SRSF1. Cell Death Discovery 8(1):24","journal-title":"Cell Death Discovery"},{"issue":"1","key":"5826_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/imr.13280","volume":"321","author":"JLGP C","year":"2024","unstructured":"C JLGP, AK ZYC (2024) Targeting ferroptosis in gastric cancer: strategies and opportunities. Immunol Rev 321(1):228\u2013245","journal-title":"Immunol Rev"},{"key":"5826_CR23","doi-asserted-by":"publisher","first-page":"1251561","DOI":"10.3389\/fonc.2023.1251561","volume":"13","author":"H Wang","year":"2023","unstructured":"Wang H, Zhang Z, Ruan S, Yan Q, Chen Y, Cui J et al (2023) Regulation of iron metabolism and ferroptosis in cancer stem cells. Front Oncol 13:1251561","journal-title":"Front Oncol"},{"key":"5826_CR24","doi-asserted-by":"crossref","unstructured":"D L, T W, J L, D Z, W C, X Z et al (2022)\u00a0Silencing TRPM2 enhanced erastin- and RSL3-induced ferroptosis in gastric cancer cells through destabilizing HIF-1\u03b1 and Nrf2 proteins. Cytotechnology 74(5):559\u2013577","DOI":"10.1007\/s10616-022-00545-z"},{"key":"5826_CR25","doi-asserted-by":"crossref","unstructured":"S S, P S (2022) Expression of ferroptosis-related gene correlates with immune microenvironment and predicts prognosis in gastric cancer. Sci Rep 12(1): 8785","DOI":"10.1038\/s41598-022-12800-6"},{"issue":"4","key":"5826_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M (2021) Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol 22(4):266\u2013282","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"5826_CR27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.chembiol.2020.02.005","volume":"27","author":"JL F","year":"2020","unstructured":"F JL, G K, DJ K, R K (2020) Autophagy-Dependent ferroptosis: machinery and regulation. Cell Chem Biology 27(4):420\u2013435","journal-title":"Cell Chem Biology"},{"key":"5826_CR28","doi-asserted-by":"publisher","unstructured":"Eddy MT, Lee M-Y, Gao Z-G, White KL, Didenko T, Horst R et al (2018) Allosteric coupling of drug binding and intracellular signaling in the A2A adenosine receptor. Cell 172(1\u20132):68\u201380.e12. https:\/\/doi.org\/10.1016\/j.cell.2017.12.004","DOI":"10.1016\/j.cell.2017.12.004"},{"key":"5826_CR29","doi-asserted-by":"publisher","unstructured":"Huang SK, Pandey A, Tran DP, Villanueva NL, Kitao A, Sunahara RK, Sljoka A, Prosser RS (2021)Delineating the conformational landscape of the adenosine A2A receptor during Gprotein coupling. Cell 184(7):1884\u20131894.e14. https:\/\/doi.org\/10.1016\/j.cell.2021.02.041","DOI":"10.1016\/j.cell.2021.02.041"},{"key":"5826_CR30","doi-asserted-by":"publisher","unstructured":"Shi L, Feng M, Du S, Wei X, Song H, Yixin X, Song J, Wenxian G (2019) Adenosine generated byregulatory T cells induces CD8 + T cell exhaustion in gastric Cancer through A2aRpathway. BioMed Res Int 4093214. https:\/\/doi.org\/10.1155\/2019\/4093214\u00a0","DOI":"10.1155\/2019\/4093214"},{"key":"5826_CR31","doi-asserted-by":"publisher","unstructured":"Sun C, Wang B, Hao S (2022) Adenosine-A2A receptor pathway in Cancer immunotherapy. Front Immunol 13. https:\/\/doi.org\/10.3389\/fimmu.2022.837230","DOI":"10.3389\/fimmu.2022.837230"},{"key":"5826_CR32","doi-asserted-by":"publisher","unstructured":"Zhang C, Wang K, Wang H (2023) Adenosine in cancer immunotherapy: taking off on a new plane. Biochim Biophys Acta (BBA) - Rev Cancer 1878(6):189005. https:\/\/doi.org\/10.1016\/j.bbcan.2023.189005","DOI":"10.1016\/j.bbcan.2023.189005"},{"key":"5826_CR33","doi-asserted-by":"publisher","unstructured":"Brand M, Kr\u00fcger J, Greve J, Theodoraki MN, Doescher J, Laban S, Schuler PJ, Hoffmann TK, Brunner C (2021) Characterization of adenosine receptor A2A (ADORA2A) mediated effects on the Immunogenic tumor microenvironment (TME) in a head and neck squamous cell carcinoma (HNSCC) mouse model. Laryngo-rhino-otologie. https:\/\/doi.org\/10.1055\/s-0041-1727936","DOI":"10.1055\/s-0041-1727936"},{"key":"5826_CR34","doi-asserted-by":"publisher","unstructured":"Young A, Ngiow SF, Gao Y, Patch A-M, Barkauskas DS, Messaoudene M et al (2023) Data from A2AR adenosine signaling suppresses natural killer cell maturation in the tumor Microenvironment. American Association for Cancer Research. Collection. https:\/\/doi.org\/10.1158\/0008-5472.c.6510590.v1","DOI":"10.1158\/0008-5472.c.6510590.v1"},{"key":"5826_CR35","doi-asserted-by":"publisher","unstructured":"Yan W, Ling L, Wu\u00a0 Y, Yang K, Liu R, Zhang J et al (2021) Structure-based design of dual-acting compounds targeting adenosine A2A receptor and histone deacetylase as novel tumor immunotherapeutic agents. J Med Chem 64(22):16573\u201316597.\u00a0 https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01155","DOI":"10.1021\/acs.jmedchem.1c01155"},{"key":"5826_CR36","doi-asserted-by":"publisher","unstructured":"Willingham S, Ho P, Leone R, Choy C, Powell J, Mccaffery I et al (2016) Adenosine A2A receptor antagonist, CPI-444, blocks adenosine-mediated T cell suppression and exhibits anti-tumor activity alone and in combination with anti-PD-1 and anti-PD-L1. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdw378.22","DOI":"10.1093\/annonc\/mdw378.22"},{"key":"5826_CR37","doi-asserted-by":"publisher","unstructured":"Klempner SJ, Sonbol MB, Wainberg ZA, Uronis HE, Chiu VK, Scott AJ et al (2024) DKN-01 in combination with tislelizumab and chemotherapy as first-line therapy in advanced gastric or gastroesophageal junction adenocarcinoma: DisTinGuish. J Clin Oncol 43(3):339\u2013349. https:\/\/doi.org\/10.1200\/JCO.24.00410","DOI":"10.1200\/JCO.24.00410"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05826-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-025-05826-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05826-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T08:11:11Z","timestamp":1759738271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-025-05826-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5826"],"URL":"https:\/\/doi.org\/10.1007\/s00018-025-05826-2","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine in strict compliance with the National Guidelines for the Care and Use of Laboratory Animals and were duly approved by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no declarations of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Disclosure statement\/Competing interests"}}],"article-number":"342"}}